Core Viewpoint - The article discusses the proposed list of key laboratories and technology innovation centers in Shanxi Province for the year 2025, highlighting the focus on various research areas including traditional medicine, veterinary medicine, and cancer treatment [2][11]. Summary by Sections Key Laboratories - The proposed list includes 69 key laboratories, such as the Research and Development of Effective Substances of Famous Jin Medicine and the Modernization of Veterinary Medicine [2][3]. - Notable institutions involved include Shanxi University, Shanxi Agricultural University, and various pharmaceutical companies [3][4]. Technology Innovation Centers - The list features 26 technology innovation centers, including the Shanxi Province Antitumor Drug Complex Preparation Technology Innovation Center and the Shanxi Province Biomolecular Imaging and Tumor Precision Diagnosis Technology Innovation Center [2][9]. - These centers aim to advance research in areas like drug development and precision medicine, with collaborations from hospitals and universities [9][10]. Public Notice - The proposed projects are open for public comment for five working days, allowing individuals and organizations to submit objections or feedback [11].

Investment Rating - The report suggests a positive outlook for the pharmacy and traditional Chinese medicine sectors, anticipating a recovery in 2026 after a weak performance in 2025 [2][5]. Core Insights - The pharmacy sector is expected to benefit from market consolidation, with leading companies likely to increase their market share through mergers and acquisitions during the industry clearing phase [3][11]. - The traditional Chinese medicine sector is projected to stabilize and potentially recover, driven by an increase in flu incidence and the upcoming update of the essential drug list [57][60]. Summary by Sections Pharmacy Sector - **Market Review**: The pharmacy sector faced significant challenges in 2025, with a decline in same-store sales and an overall reduction in the number of operating stores since Q4 2024 [5][20]. - **Policy Environment**: Regulatory measures are promoting a more compliant and healthier industry ecosystem, which is expected to benefit leading companies [14][15]. - **Market Size**: In the first ten months of 2025, the sales scale of physical pharmacies was 501.3 billion yuan, a year-on-year decrease of 1.6%, primarily due to a decline in non-pharmaceutical sales [16][21]. - **Competitive Landscape**: The number of pharmacies in China reached approximately 684,000 by the end of 2024, with a notable increase in store closures, particularly among smaller chains [20][24]. - **Marginal Performance**: There has been a slight recovery in retail sales data, with leading companies showing improved performance through cost reduction and efficiency measures [32][34]. - **Outlook for 2026**: Focus on market consolidation and the development of non-pharmaceutical products is recommended, as leading companies are expected to enhance their market share [44][52]. Traditional Chinese Medicine Sector - **Market Review**: The traditional Chinese medicine sector experienced overall weak performance in 2025, with some companies seeing temporary valuation increases due to innovative pipelines [57][58]. - **In-Hospital Opportunities**: The upcoming update of the essential drug list is expected to benefit companies with products that have the potential to be included [60]. - **Out-of-Hospital Opportunities**: An increase in flu incidence in Q4 2025 is anticipated to aid in inventory digestion, with some companies expected to see improved performance [60]. - **High Dividend Stocks**: Companies such as Lingrui Pharmaceutical, Jichuan Pharmaceutical, and Dong'e Ejiao are highlighted as stable high-dividend investment opportunities [60].

近年来，中医药滋补养生市场持续扩容。其中，六味地黄类产品作为滋阴补肾的经典品类，市场需求潜 力巨大。与此同时，传统剂型正加速向更便捷、更适口的方向创新，膏滋、口服液等新剂型日益受到当 代快节奏生活人群的青睐。华润江中敏锐洞察这一趋势，将传承千年的经典名方与现代剂型创新相结 合，为滋阴补肾市场带来一款易于服用、方便携带、高效吸收的膏滋新品，满足现代消费者对高效、便 捷、品质滋补的新需求。 12月25日，华润江中旗下六味地黄膏在京东健康首发上线，消费者即日起登录京东APP搜索"江中六味 地黄膏"即可咨询与购买，开启轻松、便捷的滋补调理新体验。 作为国民信赖的健康品牌，华润江中始于1969年，是一家集医药研发、生产与销售于一体的国有大型企 业，旗下"江中"品牌价值超466亿元，已连续22年入选中国500最具价值品牌。其位于南昌的江中药谷制 造基地，是国家级绿色工厂与智能制造的典范。2023年，华润江中牵头获批"经典名方现代中药创制全 国重点实验室"，依托4个国家级及8个省部级研发平台，构建了从药材源头到产品出厂的全链条质量管 控体系，为六味地黄膏等产品的卓越品质保驾护航。 本次新品发布是双方深度合作的又一重要里程碑 ...

Group 1: Zhongsheng Pharma - The core business of Zhongsheng Pharma has stabilized after experiencing centralized procurement, with innovative drug research and development gradually yielding results, particularly in respiratory and metabolic fields [2][4] - The company reported a revenue of 1.889 billion yuan for the first three quarters of 2025, a year-on-year decrease of 1.01%, while net profit attributable to shareholders increased by 68.40% to 251 million yuan [4] - The core products of traditional Chinese medicine have maintained stable growth post-collective procurement, with sales resilience supported by volume compensating for price reductions [4][5] - The innovative pipeline includes RAY1225 injection, a dual-target drug for weight loss and blood sugar reduction, which has shown positive results in clinical trials [5] Group 2: Medical Device Industry - The brain-computer interface (BCI) industry in China has achieved rapid development under policy support, with a focus on establishing a robust technological and industrial framework by 2027 [6][8] - The National Medical Products Administration held a meeting to discuss the advancement of BCI medical devices, emphasizing safety and effectiveness as primary considerations [17] - By 2030, the BCI industry aims to cultivate globally influential leading enterprises and a competitive industrial ecosystem, with significant advancements expected in technology and application [18]

晨光生物（300138.SZ）12月26日在投资者互动平台表示，公司建有多个符合国家药品GMP标准的现代 化生产车间，其中中药车间已于2018年通过国家药品GMP认证，具备片剂、胶囊剂、颗粒剂、丸剂四 个剂型的专业化、自动化生产能力。同时，公司还拥有十万级净化车间及完善的质量体系认证，可确保 产品质量稳定可控。目前，公司中药及配方颗粒产能在现有订单和已备案品种范围内可以满足业务需 要，具备承接集采订单的合格生产能力。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：随着中成药和中药配方颗粒逐步扩大纳入集采范围， 我公司凭借标准化和成本优势有望接连中标，请问是否已经具备了相当的产能来应对即将到来的中成药 和中药配方颗粒的大规模集采？ ...

Core Viewpoint - Beijing Tongrentang has issued an apology regarding the "Antarctic Krill Oil Fraud" incident and announced a comprehensive brand cleanup action to strictly regulate brand management systems [1] Group 1: Incident Overview - The Shanghai Consumer Protection Commission conducted tests on 15 popular Antarctic krill oil products and found that a product labeled "Beijing Tongrentang 99% High Purity Antarctic Krill Oil" contained "0" krill oil [1] - Consumers were misled into purchasing this product at a price of 50-60 yuan per bottle, while the procurement cost was only 3-4 yuan [1] Group 2: Company Background - Beijing Tongrentang, founded in 1669, is a historic Chinese medicine brand with a legacy of over 365 years, known for its commitment to quality and authenticity [1][3] - The company has a long-standing reputation, having been the sole supplier of imperial medicine during the Qing Dynasty for 188 years [1] Group 3: Implications of the Fraud - The incident highlights significant management issues within Beijing Tongrentang, as the price difference between procurement (3-3.7 yuan) and retail (over 60 yuan) is nearly 20 times [4] - The fraudulent practices not only deceive consumers but also jeopardize the brand's centuries-old reputation, which is considered a valuable asset [4] - The company is urged to take decisive action to rectify its management and restore the integrity of its brand [4]

2025年12月24日，上海久诚律师事务所股票索赔律师许峰代理的广誉远（维权）（600771）虚假陈述投 资者索赔案再向太原市中级人民法院提交一次立案。（牛彬律师专栏） 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 2025年12月24日，上海久诚律师事务所股票索赔律师许峰代理的广誉远（维权）（600771）虚假陈述投 资者索赔案再向太原市中级人民法院提交一次立案。（牛彬律师专栏） 许峰律师代理的广誉远投资者索赔案已多次向法院提交立案，目前正在等待法院的下一步安排，律师团 队还在继续推进后续案件的立案工作，还在继续接受其他投资者的索赔委托。 2024年4月11日，广誉远公告收到证监会山西监管局《行政处罚决定书》，经查明，广誉远股份违法事 实如下： 许峰律师代理的广誉远投资者索赔案已多次向法院提交立案，目前正在等待法院的下一步安排，律师团 队还在继续推进后续案件的立案工作，还在继续接受其他投资者的索赔委托。 2024年4月11日，广誉远公告收到 ...

Core Viewpoint - The recent controversy surrounding "Tongrentang (600085) Antarctic Krill Oil" has raised significant concerns due to the product's reported phospholipid content being zero, prompting regulatory scrutiny and company actions to address the issue [1][4]. Group 1: Company Actions - Tongrentang has initiated a strict brand management special action, conducting over 520 inspections of its affiliated units/stores as of December 24 [3]. - The company has filed nearly 600 complaints against infringing products on major e-commerce platforms and has targeted over 120 unauthorized stores using the Tongrentang name [3]. - Following the incident, Tongrentang has taken steps to recall the involved products and has launched a product inquiry system on its official website to assist consumers in verifying legitimate products [2][6]. Group 2: Regulatory Response - The State Administration for Market Regulation (SAMR) plans to enhance supervision of food entrusted production practices, particularly in light of the issues revealed by the Antarctic Krill Oil incident [4]. - SAMR will soon release the "Food Entrusted Production Supervision Management Measures," which will clarify the responsibilities of both parties involved in food safety during entrusted production [4]. - A special inspection will be organized to increase oversight of products like krill oil and fish oil, aiming to combat illegal activities in the market [4].

Group 1 - The company, Guilin Sanjin, reported that as of December 19, 2025, the total number of shareholders is 19,759 [2]

Core Viewpoint - Tong Ren Tang has initiated a series of special actions to address issues related to product quality and management accountability, emphasizing the importance of compliance and consumer trust [2]. Group 1: Accountability and Management Actions - The company is conducting a comprehensive investigation into the responsibilities of involved units and personnel, leading to the resignation of Li Shengyi as the general manager of Sichuan Health Company and the suspension of other related management personnel [3]. - A working group led by senior executives has been established to take over the management of Sichuan Health Company, ensuring accountability and proper handling of the situation [3]. Group 2: Regulatory Cooperation and Product Recall - Tong Ren Tang is actively cooperating with a joint investigation team from Sichuan Province, Chengdu City, and Xindu District, providing evidence related to the infringement by Sichuan Health [4]. - The company is pushing for the removal and recall of affected products from the market and is monitoring e-commerce platforms to prevent the circulation of these products [4]. Group 3: Consumer Guidance and Product Verification - A product information query system has been launched to help consumers identify genuine "Tong Ren Tang" products, which should display the "Double Dragon Mark" as a sign of authenticity [6]. - The query system includes over 1,000 entries covering traditional Chinese medicine and health food products, providing authoritative purchasing guidance [6]. Group 4: Brand Management and Compliance Actions - A special action for strict brand management has been initiated, resulting in over 520 inspections of affiliated units and stores, and nearly 600 complaints against infringing products on major e-commerce platforms [7]. - The company is taking a firm stance against unauthorized use of its brand name and trademarks, with complaints filed against over 120 stores misusing the "Tong Ren Tang" name [7].